Genfit has announced a research collaboration with EVerZom, aimed at developing regenerative technologies based on exosomes. EVerZom specializes in this innovative technology, and the agreement seeks to explore its application in multi-organ failure syndrome, particularly Acute-on-Chronic Liver Failure (ACLF).
Research and Development
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The initiative will focus on the potential of exosomes to provide therapeutic solutions in the context of ACLF. Exosomes are small vesicles secreted by cells that can play a key role in intercellular communication. The development of these technologies is still in the research phase, with the goal of providing innovative solutions for complex medical conditions.
Future Prospects
According to Genfit, this partnership could open new avenues in the field of regenerative medicine. By partnering with EVerZom, Genfit hopes to combine its biotechnology expertise with EVerZom's exosome technology to create new therapeutic opportunities. The financial details of this collaboration have not been disclosed.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 9.6M€
Risks mentioned
Dépendance aux partenaires pour le développement commercial.
Opportunities identified
Dynamique favorable des ventes d'Iqirvo renforçant les marges financières.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
